DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for generalised epilepsy — screening already-approved drugs against its 35-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGeneralised epilepsy maps to a 35-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for generalised epilepsy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
RecQ mediated genome instability 1 (RMI1) — RMI1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet bendrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3MXN · 1.55 Å · ligand BENZAMIDINE (BEN). Experimental structure, not a prediction.
What the evidence adds up to
In a cohort of 890 patients newly diagnosed at a Glasgow epilepsy unit between 1981 and 2001, 118 (13%) met criteria for idiopathic generalised epilepsy syndromes, with outcomes known for 103. Of these, 66 (64%) achieved remission, usually with a single antiepileptic drug. Sodium valproate showed a superior responder rate compared with lamotrigine (66% vs 45%, P = 0.073), and the difference was significant in juvenile myoclonic epilepsy specifically (75% vs 39%, P = 0.014). A history of febrile seizures was the only factor associated with reduced likelihood of remission (P = 0.032).
A 2000 case series described three adolescents with hemiconvulsive seizures and 3-cps generalised spike-and-wave discharges on EEG, all with normal neuroimaging. Two had been previously treated with carbamazepine, which produced only a partial response in one. All three became seizure free on sodium valproate alone or combined with lamotrigine. The authors argued that recognising these as idiopathic generalised epilepsy rather than partial seizures has important treatment implications, but the series is small and uncontrolled.
A 2003 review of acute management in idiopathic generalised epilepsy syndromes noted that myoclonic, absence, and generalised tonic-clonic seizures can present as status epilepticus, requiring acute therapy distinct from that used for secondary generalised or symptomatic convulsive seizures. A 2007 review of genetics described most epilepsies as polygenic with environmental interactions, with rare single-gene forms and microdeletions identified; progress in the preceding 15 years was said to offer new diagnostic and therapeutic possibilities, but no specific treatment data were given. A 2024 review of epileptogenesis discussed the latent period after an initial insult and molecular and cellular targets, without presenting clinical results. Another 2024 paper on neuropeptides for cognitive dysfunction in epilepsy stated that many drugs used for this purpose in the authors' country lack reliably proven effectiveness, without providing trial data.
What remains missing is prospective, controlled evidence for drug choice in adult idiopathic generalised epilepsy, particularly comparing valproate with newer agents beyond the single retrospective Glasgow cohort. No data address whether neuropeptide treatments alter cognitive outcomes, and the genetic findings have not yet translated into targeted therapies tested in clinical trials. Patient stratification by febrile seizure history or specific genetic variants is not established, and no adequately powered randomised study has resolved the valproate-versus-lamotrigine question in juvenile myoclonic epilepsy.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Outcomes of newly diagnosed idiopathic generalized epilepsy syndromes in a non-pediatric setting
AbstractINTRODUCTION: The prognosis of idiopathic generalized epilepsy syndromes (IGES) in the adult setting may vary from that in children owing to differences in genetic, environmental and lifestyle factors. METHODS: All patients diagnosed with epilepsy at the Epilepsy Unit, Western Infirmary, Glasgow, between 1981 and 2001 were reviewed. RESULTS: Of 890 patients, 118 (13%) met the criteria for IGES. Outcomes were known for 103, 66 (64%) of whom achieved remission. The responder rate with sodium valproate was superior (66% vs 45%, P = 0.073) to that with lamotrigine (LTG) particularly in patients with juvenile myoclonic epilepsies (75% vs 39%, P = 0.014). History of febrile seizures was the only factor associated with reduced likelihood of remission (P = 0.032) CONCLUSIONS: Idiopathic generalized epilepsy syndromes constituted 13% of cases in a largely adult cohort of newly diagnosed epilepsy, most of whom achieved remission usually with a single antiepileptic drug. History of febrile seizures was associated with a poorer outcome.
Dialogues in Clinical Neuroscience · 2008 · 75 citations · open access
Genetics and epilepsy
AbstractThe term "epilepsy" describes a heterogeneous group of disorders, most of them caused by interactions between several or even many genes and environmental factors. Much rarer are the genetic epilepsies that are due to single-gene mutations or defined structural chromosomal aberrations, such as microdeletions. The discovery of several of the genes underlying these rare genetic epilepsies has already considerably contributed to our understanding of the basic mechanisms in epileptogenesis. The progress made in the last 15 years in the genetics of epilepsy is providing new possibilities for diagnosis and therapy. Here, different genetic epilepsies are reviewed as examples, to demonstrate the various pathways that can lead from genes to seizures.
Acute Management of Seizures in the Syndromes of Idiopathic Generalized Epilepsies
AbstractThree of the seizure types (myoclonic, absence, and generalized tonic-clonic) and syndromes associated with idiopathic generalized or genetic epilepsies can present an acute status epilepticus picture that requires acute therapy. These are not the usual seizures observed in status epilepticus because most of these patients have secondary generalized or symptomatic generalized convulsive seizures. In this review, I discuss the unique presentation and treatment options for the acute management of seizures in the syndromes of idiopathic generalized epilepsy (IGE), with special emphasis on the seizures of status epilepticus, which persist over time or occur in a series without recovery of consciousness.
Understanding epileptogenesis from molecules to network alteration
AbstractEpilepsy is characterized by recurrent seizures. Following an initial insult, a latent period precedes the onset of spontaneous seizures, a process referred to as epileptogenesis. This period plays a critical role in halting the progression toward epilepsy before the onset of abnormal molecular and network alterations. In this study, the fundamental concepts of epileptogenesis as well as the associated molecular and cellular targets are reviewed.
Idiopathic Generalized Epilepsy Presenting With Hemiconvulsive Seizures
AbstractPURPOSE: Unilateral seizures, or hemiconvulsive attacks, are motor seizures with tonic and/or clonic phenomena that involve only one side of the body. METHODS: We describe three adolescents who presented with hemiconvulsive seizures and were found to have 3-cps generalized spike-and-wave discharges on ictal and/or interictal EEG. All had normal neuroimaging studies. Two patients had been previously treated with carbamazepine, which led to a partial response in one patient. RESULTS: All three patients, however, are now seizure free on either sodium valproate or a combination of sodium valproate and lamotrigine. We believe the electroclinical diagnosis is that of idiopathic generalized epilepsy. CONCLUSIONS: Idiopathic generalized epilepsy presenting with hemiconvulsive seizures has not, to our knowledge, been previously described. However, the correct diagnosis of an idiopathic generalized seizure disorder, as opposed to a partial seizure disorder, has important treatment implications. The possible mechanism of hemiconvulsive seizures in idiopathic generalized epilepsy is discussed.
Zenodo (CERN European Organization for Nuclear Research) · 2024 · 0 citations · open access
THE VALUE OF NEUROPEPTIDES IN THE TREATMENT OF PATIENTS WITH COGNITIVE DYSFUNCTION IN EPILEPSY
AbstractManagement of patients with epilepsy is a serious problem of modern medicine Lack of timely and adequate treatment of patients with epilepsy leads to the occurrence of irreversible anatomical and functional changes in the brain. To improve the effectiveness of treatment of patients with epilepsy in our country, drugs are used, the effectiveness and feasibility of many of which are not reliably proven.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works using Disease Ontology synonyms, resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
